Literature DB >> 12498717

Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma.

Keishi Yamashita1, Sunil Upadhyay, Motonobu Osada, Mohammad O Hoque, Yan Xiao, Masaki Mori, Fumiaki Sato, Stephen J Meltzer, David Sidransky.   

Abstract

We performed a comprehensive survey of commonly inactivated tumor suppressor genes in esophageal squamous cell carcinoma (ESCC) based on functional reactivation of epigenetically silenced tumor suppressor genes by 5-aza-2'-deoxycytidine and trichostatin A using microarrays containing 12599 genes. Among 58 genes identified by this approach, 44 (76%) harbored dense CpG islands in the promoter regions. Thirteen of twenty-two tested gene promoters were methylated in cell lines, and ten in primary ESCC accompanied by silencing at the mRNA level. Potent growth suppressive activity of three genes including CRIP-1, Apolipoprotein D, and Neuromedin U in ESCC cells was demonstrated by colony focus assays. Pharmacologic reversal of epigenetic silencing is a powerful approach for comprehensive identification of tumor suppressor genes in human cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498717     DOI: 10.1016/s1535-6108(02)00215-5

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  117 in total

Review 1.  Krüppel cripples prostate cancer: KLF6 progress and prospects.

Authors:  Goutham Narla; Scott L Friedman; John A Martignetti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

2.  Clinical and public health research using methylated DNA immunoprecipitation (MeDIP): a comparison of commercially available kits to examine differential DNA methylation across the genome.

Authors:  Priscilla Brebi-Mieville; Carmen Ili-Gangas; Pamela Leal-Rojas; Maartje G Noordhuis; Ethan Soudry; Jimena Perez; Juan Carlos Roa; David Sidransky; Rafael Guerrero-Preston
Journal:  Epigenetics       Date:  2012-01-01       Impact factor: 4.528

3.  Inactivation of the tumor suppressor Krüppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas.

Authors:  Xiu-cheng Pan; Zhi Chen; Feng Chen; Xiao-hong Chen; Han-yin Jin; Xiao-yan Xu
Journal:  J Zhejiang Univ Sci B       Date:  2006-10       Impact factor: 3.066

Review 4.  Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology.

Authors:  Pedro Jares; Elías Campo
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

5.  Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression.

Authors:  Chun-Han Chen; Po-Hsien Huang; Po-Chen Chu; Mei-Chuan Chen; Chih-Chien Chou; Dasheng Wang; Samuel K Kulp; Che-Ming Teng; Qianben Wang; Ching-Shih Chen
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

6.  TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction.

Authors:  Luisa M Botella; Francisco Sanz-Rodriguez; Yusuke Komi; Africa Fernandez-L; Elisa Varela; Eva M Garrido-Martin; Goutham Narla; Scott L Friedman; Soichi Kojima
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

Review 7.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

8.  Epigenetic modulation of the muscarinic type 3 receptor in salivary epithelial cells.

Authors:  Yong-Hwan Shin; Meihong Jin; Sung-Min Hwang; Seul-Ki Choi; Eun Namkoong; Minkyoung Kim; Moon-Yong Park; Se-Young Choi; Jong-Ho Lee; Kyungpyo Park
Journal:  Lab Invest       Date:  2014-12-08       Impact factor: 5.662

9.  Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.

Authors:  Marilia F Calmon; Rodrigo V Rodrigues; Carla M Kaneto; Ricardo P Moura; Sabrina D Silva; Louise Danielle C Mota; Daniel G Pinheiro; Cesar Torres; Alex F de Carvalho; Patrícia M Cury; Fabio D Nunes; Ines Nobuko Nishimoto; Fernando A Soares; Adriana M A da Silva; Luis P Kowalski; Helena Brentani; Cleslei F Zanelli; Wilson A Silva; Paula Rahal; Eloiza H Tajara; Dirce M Carraro; Anamaria A Camargo; Sandro R Valentini
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

10.  Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2.

Authors:  Jennifer A Anderton; Janet C Lindsey; Meryl E Lusher; Richard J Gilbertson; Simon Bailey; David W Ellison; Steven C Clifford
Journal:  Neuro Oncol       Date:  2008-07-29       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.